Cortisol Blocker Compositions with Rapid Saliva Diagnostics

Solution Overview

Problem

Current diagnostic methods for determining cortisol levels are costly, laborious, and time-consuming, preventing rapid quantitative determination necessary for assigning treatment with glucocorticoid receptor (GCR) antagonists, and there is a need for effective therapies for treatment-resistant cancers and chronic viral infections.

Innovation Solution

Development of a low-cost, rapid response diagnostic system using a saliva-based device to quantify cortisol levels and a combination of GR antagonists (e.g., ORG 34517, PT150, PT155) for targeted therapy, including direct tumor treatment and chemosensitization of tumors with high GR expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current diagnostic methods are used to determine cortisol levels, then measurement accuracy is maintained, but cost, labor requirements, and time consumption increase significantly

Engineering Contradiction:

Improvecortisol level measurement accuracyVSAvoidtime for cortisol determination

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent replaces complex mechanical/chemical diagnostic systems with a biosensor-based optical detection system. The cortisol measurement is achieved through a biosensor that converts biochemical interactions into optical signals, eliminating the need for laborious mechanical processing and chemical assays while maintaining measurement accuracy and enabling rapid results.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces a biosensor as an intermediary device between the cortisol sample and the measurement system. This biosensor acts as a mediator that specifically binds to cortisol and transduces the binding event into a measurable signal, simplifying the overall diagnostic process while preserving measurement precision.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If current diagnostic methods are used to determine cortisol levels, then measurement accuracy is maintained, but operational complexity and cost increase

Engineering Contradiction:

Improvecortisol level measurement accuracyVSAvoidsimplicity of cortisol determination

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent replaces complex mechanical/chemical diagnostic systems with a biosensor-based optical detection system. The cortisol measurement is achieved through a biosensor that converts biochemical interactions into optical signals, eliminating the need for laborious mechanical processing and chemical assays while maintaining measurement accuracy and enabling rapid results.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The biosensor system performs self-identification and self-measurement of cortisol levels without requiring complex operational procedures. The sensor automatically binds to cortisol in the sample and generates a measurable signal, making the diagnostic process simple and accessible while maintaining high measurement precision.

Inventive Principle:

Principle #25Self-service

3Reliability

If glucocorticoid receptor antagonists are administered, then treatment efficacy for viral infections and cancer improves, but patient selection accuracy must increase to avoid unnecessary treatment

Engineering Contradiction:

Improvetreatment efficacyVSAvoidpatient selection accuracy

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent replaces complex mechanical/chemical diagnostic systems with a biosensor-based optical detection system. The cortisol measurement is achieved through a biosensor that converts biochemical interactions into optical signals, eliminating the need for laborious mechanical processing and chemical assays while maintaining measurement accuracy and enabling rapid results.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent implements a feedback mechanism where cortisol measurement results directly inform treatment decisions. The rapid and accurate cortisol level determination provides immediate feedback that guides whether a patient should receive glucocorticoid receptor antagonist therapy, ensuring that treatment is targeted to appropriate patients and improving both selection accuracy and treatment efficacy.

Inventive Principle:

Principle #23Feedback

Data Source

PatentEP3400233B1Pharmaceutical compositions and methods

Publication Date: 2025.10.22 POP TEST ONCOLOGY LLC

Figure 1
Figure 2
Figure 3

AI summary

This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.